140 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28621538	63	Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.	Novartis Pharma
28085275	53	Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.	Bristol-Myers Squibb
28045547	73	Peptide Macrocycle Inhibitor of Coagulation Factor XII with Subnanomolar Affinity and High Target Selectivity.	Ecole Polytechnique F�D�Rale De Lausanne (Epfl)
28197309	40	Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors.	Global Blood Therapeutics
27994741	48	Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.	Bristol-Myers Squibb R & D
27455395	66	Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.	Bristol-Myers Squibb R & D
27073051	71	Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.	Bristol-Myers Squibb
26704266	80	Novel phenylalanine derived diamides as Factor XIa inhibitors.	Bristol-Myers Squibb
25592713	37	Pyridine and pyridinone-based factor XIa inhibitors.	Bristol-Myers Squibb
26151189	56	Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.	TBA
26005539	23	Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.	Bristol-Myers Squibb
25728130	79	Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.	Bristol-Myers Squibb
24951330	25	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.	Bristol-Myers Squibb
25405503	109	Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.	Bristol-Myers Squibb
24900827	8	Inhibitors of Factor XIa and Plasma Kallikrein May Treat Thromboembolic Disorders and Many Diabetes Complications.	Therachem Research Medilab (India)
660589	3	Inactivation of trypsin-like proteases by sulfonylation. Variation of positively charged group and inhibitor length.	TBA
24613052	69	Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin.	Hiroshima International University
23586812	38	Development of a selective peptide macrocycle inhibitor of coagulation factor XII toward the generation of a safe antithrombotic therapy.	Ecole Polytechnique F�D�Rale De Lausanne Epfl
23294255	114	Development of new cyclic plasmin inhibitors with excellent potency and selectivity.	Philipps University Marburg
16644215	52	Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.	Celera Genomics
22276953	63	A new strategy for the development of highly potent and selective plasmin inhibitors.	Philipps University Marburg
22386244	4	Human kallikrein 6 inhibitors with a para-amidobenzylanmine P1 group identified through virtual screening.	Sanofi Pharmaceuticals
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
18053726	364	Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.	Johnson & Johnson Pharmaceutical Research & Development
18054227	45	Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.	Bristol-Myers Squibb Research and Development
17588746	103	SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.	Bristol-Myers Squibb
16250649	10	Selective inhibitors of the serine protease plasmin: probing the S3 and S3' subsites using a combinatorial library.	Brown University
14640539	112	Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).	Pharmaceutical Research Institute
11170646	106	Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.	Dupont Pharmaceuticals
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
9357536	47	Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position.	Merck Research Laboratories
9301673	234	Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.	Klinikum Der Friedrich-Schiller-Universit£T Jena
8478905	53	Inhibition studies of some serine and thiol proteinases by new leupeptin analogues.	University of Arkansas
10091673	21	Synthesis of potent and selective inhibitors of human plasma kallikrein.	The Procter & Gamble
	24	L-373,890, An achiral, noncovalent, subnanomolar thrombin inhibitor	TBA
22047802	8	The arginine mimickingß-amino acidß³hPhe(3-H2N-CH2) as S1 ligand in cyclotheonamide-basedß-tryptase inhibitors.	Universit£T Bielefeld
21995444	32	Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.	Astellas Pharma
21944858	12	Identification of novel plasmin inhibitors possessing nitrile moiety as warhead.	Hiroshima International University
21741839	83	Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT.	Philipps University Marburg
19483697	23	Phage-encoded combinatorial chemical libraries based on bicyclic peptides.	Laboratory of Molecular Biology, Medical Research Council
	13	Characterization of LY806303 as a potent and selective inhibitor of thrombin	TBA
17643988	92	Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications.	Bristol-Myers Squibb
17420122	18	Selective and dual action orally active inhibitors of thrombin and factor Xa.	Glaxosmithkline
16725321	13	Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.	Celera Genomics
16413183	16	Small molecule inhibitors of plasma kallikrein.	Celera Genomics
16213711	37	Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
15013007	319	Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity.	Millennium Pharmaceuticals
14711304	117	Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.	Abbott Laboratories
32551603	185	Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach.	Novartis Institutes For Biomedical Research
32456431	24	Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.	Bristol Myers Squibb
27434175	54	Substrate-Guided Design of Selective FXIIa Inhibitors Based on the Plant-Derived Momordica cochinchinensis Trypsin Inhibitor-II (MCoTI-II) Scaffold.	The University of Queensland
27280436	304	Optimization of Cyclic Plasmin Inhibitors: From Benzamidines to Benzylamines.	Philipps University Marburg
30707839	63	Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides.	Chinese Academy of Sciences
31679971	44	6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.	University of Wollongong
10560742	85	3-Amidinophenylalanine-based inhibitors of urokinase.	UniversitäT Jena
31521475	205	Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.	Glaxosmithkline
31005442	64	Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.	Glaxosmithkline R&D
29851477	6	New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm.	Astrazeneca
30520638	54	Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma.	The University of Queensland
31833761	32	Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.	Bristol-Myers Squibb
31658420	98	Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.	Philipps University Marburg
9784099	84	Design of benzamidine-type inhibitors of factor Xa.	Institut FüR Biochemie
9703466	35	Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.	Merck Research Laboratories
30613336	32	Potent, Selective, and Cell-Penetrating Inhibitors of Kallikrein-Related Peptidase 4 Based on the Cyclic Peptide MCoTI-II.	The University of Queensland
9171866	12	Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.	Merck Research Laboratories
31563807	63	Discovery of novel, potent, isosteviol-based antithrombotic agents.	Peking University
26575094	60	Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.	University of Antwerp (Ua)
26536069	89	Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor.	Aarhus University
29072911	16	Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs.	University of Nottingham
29501396	59	Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors.	Bristol-Myers Squibb
30130401	71	6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.	University of Wollongong
28835783	6	Plasma Kallikrein Inhibitors for the Treatment of Retinal Vascular Permeability Associated with Diabetic Retinopathy and Diabetic Macular Edema.	Therachem Research Medilab (India)
29517911	87	Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.	Bicycle Therapeutics
29077405	63	Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).	Bristol-Myers Squibb
28460818	29	Neutral macrocyclic factor VIIa inhibitors.	Bristol-Myers Squibb Research and Development
	18	Novel multi-targeted agents for Alzheimer's disease: Synthesis, biological evaluation, and molecular modeling of novel 2-[4-(4-substitutedpiperazin-1-yl)phenyl]benzimidazoles	Hacettepe University
8910390	13	Molecular and pharmacological characterization of native cortical gamma-aminobutyric acidA receptors containing both alpha1 and alpha3 subunits.	Universidad De Sevilla
19199284	24	Development and biological evaluation of a novel aurora A kinase inhibitor.	Parc De Recerca Biomedica De Barcelona
8097479	3	A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides.	University of Toronto
16407991	13	Activity-based probes that target diverse cysteine protease families.	Stanford University
20550146	32	Correlating solution binding and ESI-MS stabilities by incorporating solvation effects in a confined cucurbit[8]uril system.	University of Cambridge
19699645	12	Design, synthesis, and biological evaluation of hydroquinone derivatives as novel inhibitors of the sarco/endoplasmic reticulum calcium ATPase.	Northern Kentucky University
15911271	22	Inhibition of IKK-2 by 2-[(aminocarbonyl)amino]-5-acetylenyl-3-thiophenecarboxamides.	Pfizer
17292610	17	Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.	University of Tokyo
18260617	131	3-Amino-benzo[d]isoxazoles as Novel Multitargeted Inhibitors of Receptor Tyrosine Kinases.	Abbott Laboratories
18020435	55	4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.	Vernalis (R&D)
16539374	16	Synthesis, pharmacological evaluation, and molecular modeling studies of novel peptidic CAAX analogues as farnesyl-protein-transferase inhibitors.	Universita Di Napoli Federico Ii
15863311	244	Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors.	Merck Research Laboratories
11101352	88	Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.	Parke-Davis Pharmaceutical Research
24058293	12	Modulation of global low-frequency motions underlies allosteric regulation: demonstration in CRP/FNR family transcription factors.	Durham University
11784141	11	Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.	University of Queensland